Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)

BACKGROUND: This study is an outcome evaluation of the Drug-Eluting-Bead-Chemoembolization (DEB TACE) compared to conventional TACE (cTACE) with Cisplation and Lipiodol in patients with hepatocellular carcinoma (HCC) and Child-Pugh A Cirrhosis. MATERIAL/METHODS: A comparison of interventional therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiggermann, Philipp, Sieron, Dominik, Brosche, Christiane, Brauer, Thomas, Scheer, Fabian, Platzek, Ivan, Wawrzynek, Wojciech, Stroszczynski, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539521/
https://www.ncbi.nlm.nih.gov/pubmed/21455104
http://dx.doi.org/10.12659/MSM.881714
_version_ 1782255103822004224
author Wiggermann, Philipp
Sieron, Dominik
Brosche, Christiane
Brauer, Thomas
Scheer, Fabian
Platzek, Ivan
Wawrzynek, Wojciech
Stroszczynski, Christian
author_facet Wiggermann, Philipp
Sieron, Dominik
Brosche, Christiane
Brauer, Thomas
Scheer, Fabian
Platzek, Ivan
Wawrzynek, Wojciech
Stroszczynski, Christian
author_sort Wiggermann, Philipp
collection PubMed
description BACKGROUND: This study is an outcome evaluation of the Drug-Eluting-Bead-Chemoembolization (DEB TACE) compared to conventional TACE (cTACE) with Cisplation and Lipiodol in patients with hepatocellular carcinoma (HCC) and Child-Pugh A Cirrhosis. MATERIAL/METHODS: A comparison of interventional therapy with either cTACE or DEB-TACE of 22 patients each with unresectable HCC and Child-Pugh A Cirrhosis was carried out. A comparison of therapy-associated complications, tumour response rates and mean survival was performed. Tumour response was evaluated in accordance with the European Association for the Study of the Liver (EASL) response criteria by two radiologists in consensus reading. RESULTS: The choice of TACE procedure (DEB TACE/cTACE) had no significant impact on therapy-associated complications. Objective Response (OR, complete response + partial response) for DEB-TACE was 22.7%; a further 68.2% was stable disease (SD). The respective response rates for the cTACE were OR 22.7 and SD 31.8%. Thus disease control was not significantly increased for DEB TACE (p=0.066). After DEB-TACE mean survival was significantly prolonged with 651±76 days vs. 414±43 days for cTACE (p=0.01). CONCLUSIONS: Associated with a similar safety profile and an at least comparable tumour response, the DEB-TACE is a method of treatment for HCC that has the potential to improve mean survival compared to cTACE with Cisplatin/Lipiodol.
format Online
Article
Text
id pubmed-3539521
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-35395212013-04-24 Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE) Wiggermann, Philipp Sieron, Dominik Brosche, Christiane Brauer, Thomas Scheer, Fabian Platzek, Ivan Wawrzynek, Wojciech Stroszczynski, Christian Med Sci Monit Clinical Research BACKGROUND: This study is an outcome evaluation of the Drug-Eluting-Bead-Chemoembolization (DEB TACE) compared to conventional TACE (cTACE) with Cisplation and Lipiodol in patients with hepatocellular carcinoma (HCC) and Child-Pugh A Cirrhosis. MATERIAL/METHODS: A comparison of interventional therapy with either cTACE or DEB-TACE of 22 patients each with unresectable HCC and Child-Pugh A Cirrhosis was carried out. A comparison of therapy-associated complications, tumour response rates and mean survival was performed. Tumour response was evaluated in accordance with the European Association for the Study of the Liver (EASL) response criteria by two radiologists in consensus reading. RESULTS: The choice of TACE procedure (DEB TACE/cTACE) had no significant impact on therapy-associated complications. Objective Response (OR, complete response + partial response) for DEB-TACE was 22.7%; a further 68.2% was stable disease (SD). The respective response rates for the cTACE were OR 22.7 and SD 31.8%. Thus disease control was not significantly increased for DEB TACE (p=0.066). After DEB-TACE mean survival was significantly prolonged with 651±76 days vs. 414±43 days for cTACE (p=0.01). CONCLUSIONS: Associated with a similar safety profile and an at least comparable tumour response, the DEB-TACE is a method of treatment for HCC that has the potential to improve mean survival compared to cTACE with Cisplatin/Lipiodol. International Scientific Literature, Inc. 2011-04-01 /pmc/articles/PMC3539521/ /pubmed/21455104 http://dx.doi.org/10.12659/MSM.881714 Text en © Med Sci Monit, 2011 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
spellingShingle Clinical Research
Wiggermann, Philipp
Sieron, Dominik
Brosche, Christiane
Brauer, Thomas
Scheer, Fabian
Platzek, Ivan
Wawrzynek, Wojciech
Stroszczynski, Christian
Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)
title Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)
title_full Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)
title_fullStr Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)
title_full_unstemmed Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)
title_short Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)
title_sort transarterial chemoembolization of child-a hepatocellular carcinoma: drug-eluting bead tace (deb tace) vs. tace with cisplatin/lipiodol (ctace)
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539521/
https://www.ncbi.nlm.nih.gov/pubmed/21455104
http://dx.doi.org/10.12659/MSM.881714
work_keys_str_mv AT wiggermannphilipp transarterialchemoembolizationofchildahepatocellularcarcinomadrugelutingbeadtacedebtacevstacewithcisplatinlipiodolctace
AT sierondominik transarterialchemoembolizationofchildahepatocellularcarcinomadrugelutingbeadtacedebtacevstacewithcisplatinlipiodolctace
AT broschechristiane transarterialchemoembolizationofchildahepatocellularcarcinomadrugelutingbeadtacedebtacevstacewithcisplatinlipiodolctace
AT brauerthomas transarterialchemoembolizationofchildahepatocellularcarcinomadrugelutingbeadtacedebtacevstacewithcisplatinlipiodolctace
AT scheerfabian transarterialchemoembolizationofchildahepatocellularcarcinomadrugelutingbeadtacedebtacevstacewithcisplatinlipiodolctace
AT platzekivan transarterialchemoembolizationofchildahepatocellularcarcinomadrugelutingbeadtacedebtacevstacewithcisplatinlipiodolctace
AT wawrzynekwojciech transarterialchemoembolizationofchildahepatocellularcarcinomadrugelutingbeadtacedebtacevstacewithcisplatinlipiodolctace
AT stroszczynskichristian transarterialchemoembolizationofchildahepatocellularcarcinomadrugelutingbeadtacedebtacevstacewithcisplatinlipiodolctace